DK0646379T3 - Insulinformulering - Google Patents

Insulinformulering

Info

Publication number
DK0646379T3
DK0646379T3 DK94305883T DK94305883T DK0646379T3 DK 0646379 T3 DK0646379 T3 DK 0646379T3 DK 94305883 T DK94305883 T DK 94305883T DK 94305883 T DK94305883 T DK 94305883T DK 0646379 T3 DK0646379 T3 DK 0646379T3
Authority
DK
Denmark
Prior art keywords
insulin
formulation
zinc
total
present
Prior art date
Application number
DK94305883T
Other languages
Danish (da)
English (en)
Inventor
James Arthur Hoffmann
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0646379T3 publication Critical patent/DK0646379T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94305883T 1993-08-13 1994-08-09 Insulinformulering DK0646379T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/106,106 US5534488A (en) 1993-08-13 1993-08-13 Insulin formulation

Publications (1)

Publication Number Publication Date
DK0646379T3 true DK0646379T3 (da) 2001-12-03

Family

ID=22309529

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94305883T DK0646379T3 (da) 1993-08-13 1994-08-09 Insulinformulering

Country Status (27)

Country Link
US (1) US5534488A (es)
EP (1) EP0646379B1 (es)
JP (1) JPH07149660A (es)
KR (1) KR950005324A (es)
CN (1) CN1109364A (es)
AT (1) ATE207761T1 (es)
AU (1) AU674975B2 (es)
BR (1) BR9403204A (es)
CA (1) CA2129763A1 (es)
CO (1) CO4230235A1 (es)
CZ (1) CZ193794A3 (es)
DE (1) DE69428860T2 (es)
DK (1) DK0646379T3 (es)
ES (1) ES2164691T3 (es)
HU (1) HUT67853A (es)
IL (1) IL110581A0 (es)
NO (1) NO942959L (es)
NZ (1) NZ264197A (es)
PE (1) PE14495A1 (es)
PH (1) PH30757A (es)
PL (1) PL177002B1 (es)
PT (1) PT646379E (es)
RU (1) RU2135205C1 (es)
TW (1) TW326394B (es)
UA (1) UA27874C2 (es)
YU (1) YU50494A (es)
ZA (1) ZA945939B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578238A (en) * 1992-10-30 1996-11-26 Lord Corporation Magnetorheological materials utilizing surface-modified particles
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
WO2001000675A1 (en) * 1999-06-29 2001-01-04 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
AU4935701A (en) * 2000-03-24 2001-10-08 Genentech Inc Use of insulin for the treatment of cartilagenous disorders
EP1247283B1 (en) 2000-10-06 2006-08-16 The Adviser - Defence Research & Development Organisation A magneto sensitive fluid composition and a process for preparation thereof
WO2002045102A1 (en) * 2000-11-29 2002-06-06 The Adviser Defence Research & Development Organisation, Ministry Of Defence, Government Of India A magnetorheological fluid composition and a process for preparation thereof
JP4489352B2 (ja) * 2001-02-09 2010-06-23 ジェネンテック, インコーポレイテッド Igf−1の結晶化
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CA2471144C (en) 2002-01-09 2011-06-07 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
CA2553392A1 (en) * 2004-01-16 2005-08-11 Biodel Inc Sublingual drug delivery device
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
PT2319500E (pt) * 2004-03-12 2013-01-23 Biodel Inc Composições de distribuição de fármacos de actuação rápida
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
SG153039A1 (en) 2004-05-06 2009-06-29 Emisphere Tech Inc Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate
AU2005249410A1 (en) * 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
WO2006017541A2 (en) * 2004-08-03 2006-02-16 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US20060078622A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP2012817A2 (en) * 2006-04-12 2009-01-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
PL2203181T3 (pl) 2007-10-16 2018-07-31 Biocon Limited Podawana doustnie stała kompozycja farmaceutyczna i jej sposób
CA2711561A1 (en) * 2008-01-04 2009-07-16 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
CA3016451A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
SG183106A1 (en) * 2010-02-22 2012-09-27 Univ Case Western Reserve Long-acting insulin analogue preparations in soluble and crystalline forms
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2680861B1 (en) 2011-03-01 2022-05-04 Nutrition 21, LLC Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
HUE062573T2 (hu) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Glargin inzulin/lixiszenatid rögzített arányú készítmény
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
WO2017139337A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882202A (en) * 1950-04-05 1959-04-14 Novo Terapeutisk Labor As Insulin crystal preparations and methods of producing them
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Also Published As

Publication number Publication date
ATE207761T1 (de) 2001-11-15
KR950005324A (ko) 1995-03-20
AU7024794A (en) 1995-02-23
PT646379E (pt) 2002-03-28
HU9402287D0 (en) 1994-09-28
PE14495A1 (es) 1995-06-02
NZ264197A (en) 1997-01-29
CA2129763A1 (en) 1995-02-14
UA27874C2 (uk) 2000-10-16
PL304600A1 (en) 1995-02-20
CZ193794A3 (en) 1995-03-15
JPH07149660A (ja) 1995-06-13
IL110581A0 (en) 1994-11-11
RU2135205C1 (ru) 1999-08-27
NO942959L (no) 1995-02-14
TW326394B (en) 1998-02-11
AU674975B2 (en) 1997-01-16
PL177002B1 (pl) 1999-09-30
DE69428860D1 (de) 2001-12-06
CO4230235A1 (es) 1995-10-19
YU50494A (sh) 1997-01-08
HUT67853A (en) 1995-05-29
ZA945939B (en) 1996-02-08
NO942959D0 (no) 1994-08-09
CN1109364A (zh) 1995-10-04
BR9403204A (pt) 1995-04-18
DE69428860T2 (de) 2002-05-02
ES2164691T3 (es) 2002-03-01
EP0646379A1 (en) 1995-04-05
EP0646379B1 (en) 2001-10-31
PH30757A (en) 1997-10-17
US5534488A (en) 1996-07-09

Similar Documents

Publication Publication Date Title
ATE207761T1 (de) Insulin formulierung
AU610636B2 (en) Stabilised human protein preparations
ES8101382A1 (es) Un procedimiento para la obtencion de un aglutinante para los tejidos a base de proteinas humanas o animales
GB9108652D0 (en) Immunoreactive compounds
CA2015186A1 (en) Nutrient composition
AU2670495A (en) Ifn-beta liquid formulations
AU8188087A (en) Variants of hirudin, their use and their preparation
EP0511903A3 (en) Conjugate of calcitonin and polyethylene glycol
AU624079B2 (en) Novel fluorinated derivatives of amino acids usable more particularly as surfactants or cosurfactants and preparations for biomedical use incorporating these derivatives
AU6406590A (en) Porcine lactoferrin amino acid and cdna sequence
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
MD1714G2 (ro) Compoziţie terapeutică în formă de sirop, conţinând N-acetilcisteină
ATE149354T1 (de) Pharmazeutische zusammensetzung von stabilisiertem (leu 13>-motilin-hse
ATE262307T1 (de) Verwendung von goldlegierungen für konstruktionselemente in der dentaltechnik
CA2153071A1 (en) Derivatized calcitonins
GR3007486T3 (es)
EP0292302A3 (en) Human splenin
CA2247998A1 (en) Fragments of cr1 and their use
HU201445B (en) Herbicide composition containing sulfonyl-urea derivative as active component and glycinamide derivative as antidotum
TH17521EX (th) สูตรผสมอินซูลิน